Get the Stockscreener App
299.04
0.21%
0.63
Pre-market:
302.50
3.46
+1.16%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $299.04, with a volume of 209.34K.
It is up +0.21% in the last 24 hours and up +6.73% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$298.41
Open:
$296.95
24h Volume:
209.34K
Relative Volume:
0.62
Market Cap:
$5.96B
Revenue:
$274.48M
Net Income/Loss:
$153.56M
P/E Ratio:
40.55
EPS:
7.3755
Net Cash Flow:
$114.06M
1W Performance:
+5.04%
1M Performance:
+6.73%
6M Performance:
+48.29%
1Y Performance:
+76.99%
1-Day Range:
$296.37
$303.41
1-Week Range:
$280.49
$303.41
52-Week Range:
$163.45
$326.63
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
299.04 | 5.96B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | BofA Securities | Buy |
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Barclays initiates Ligand Pharma stock with overweight rating By Investing.com - Investing.com Canada
US53220KAJ7 Bond Profile: Coupon and Redemption - TradingView
Ligand Pharmaceuticals Director Martine Zimmermann Reports RSU Tax Withholding on 115 Shares - Kalkine Media
Form 4 Ligand Pharmaceuticals Incorporated For: 24 September By Investing.com - Investing.com Canada
Ligand, AvenCell ink financing deal worth up to $47M for CAR-T therapies - TradingView
LGND Reiterated by HC Wainwright & Co. -- Price Target Maintained at $358 - gurufocus.com
LGND Looks 60.8% Overvalued on GF Value™ - gurufocus.com
Oppenheimer reiterates Ligand Pharma stock rating on AvenCell deal By Investing.com - Investing.com Canada
LGND Looks 60.6% Overvalued on GF Value™ - gurufocus.com
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell - marketscreener.com
Up to $47 million could help advance AvenCell's treatments for two blood cancers. - Stock Titan
Ligand and AvenCell Therapeutics Enter Financing Agreement - GlobeNewswire
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
McDermott Will & Schulte advises Ligand Pharmaceuticals in $23 million acquisition of royalty and milestone interest in Santen’s Ryjunea® - mcdermottlaw.com
LGND Maintained by Citigroup -- Price Target Raised to $397 - gurufocus.com
Sydnexis sells Ryjunea EMEA royalty rights to Ligand for $23 million upfront - The Pharma Letter
Ligand Acquires Royalty Rights in Santen’s Ryjunea from Sydnexis for $23 Million - VisionMonday.com
LGND Looks 56.0% Overvalued on GF Value™ - gurufocus.com
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® - Yahoo Finance
A production platform used in six approved biologics gets new funding. Primrose Bio will help expand its reach. - Stock Titan
Ligand Acquires Ryjunea Royalty Rights From Sydnexis for $23 Million - Minichart
Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million - Yahoo Finance
Ligand Acquires Ryjunea EMEA Royalty Rights for $23M Upfront - TradingView
About 1 in 3 European children and teens may be nearsighted by 2050. Ligand buys rights to a children's eye drop. - Stock Titan
LGNZZ 8-K FilingsLIGAND PHARMS BETA CVR SEC 8-K - Stock Titan
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million - Yahoo Finance
Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years - Benzinga
Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold - Seeking Alpha
Ligand Pharmaceuticals seen as a strong midcap pharma despite recent 10% drop, with promising royalty assets. - Pluang
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big - Stock Titan
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued? - simplywall.st
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock - Investing.com
Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book - Yahoo Finance
Ligand (NASDAQ: LGND) insider to sell 15,000 shares after plan trades - Stock Titan
XOMA Royalty Reports $41.2M First-Half Net Loss on Trial Failures - Minichart
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
A cash-heavy royalty arm at Ligand (NASDAQ: LGND) is loss-making - Stock Titan
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale By Investing.com - Investing.com Canada
Ligand to Participate in September Investor Conferences - marketscreener.com
Ligand (LGND) Snapshot: Ends Down by 2.13% at $280.18 for the Current Session; Price Setup: the Supplied Trading Band Runs From $266.17 to $294.19 at the CloseEarnings Breakout Stocks - vinanet.vn
Ligand (LGND) Chart: Retreats 0.38% to $286.29 in Latest Trading; Chart Watch: $271.98 and $300.60 Define the Nearby Reference Levels in the Available RecordMomentum Trade - vinanet.vn
$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga
LGND6487833 Bond Profile — Key Metrics - TradingView
LGND6487833 Bond Yield and Price — FINRA:LGND6487833 - TradingView
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):